pharma news

May 26, 2020

Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19.  The company has submitted the IND with the US FDA for its planned multinational Phase 2b/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients ...

May 21, 2020

CanSino adds mRNA with Precision NanoSystems  CanSino Biologics is already evaluating a recombinant coronavirus vaccine in China. However, it is adding the mRNA to COVID-19 vaccine through a licensing agreement with Precision NanoSystems. The partners will work on an mRNA nanoparticle vaccine for COVID-1...

May 14, 2020

Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising.  The drug limited tumour growth in 43% and shrank tumors in 28% of patients...

May 12, 2020

MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...

May 07, 2020

Avrobio taps ADC of Magenta for enhancing gene therapy conditioning Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to check antibody-drug conjugate. Under the agreement, the partners will evaluate Magenta’s lead conditioning program, MGTA-117, with at lea...

May 05, 2020

Florence-based Menarini Group has announced a USD667 million acquisition of the Stemline Therapeutics, an oncology-focused company. As per the agreement, Menarini plans to help Stemline to build a strong foothold in the U.S., and will also continue the development of Elzonris, a CD123 targeted therapy. Th...

Apr 30, 2020

Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against p...

Apr 23, 2020

AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson's disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a famil...

Apr 21, 2020

The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer Genetics Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capec...

Apr 16, 2020

Vir's Hepatitis B drug shows positive results in phase 2 The hepatitis B drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the hepatitis B surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs. The drug, VIR-2218,...